Morningstar Investment Management LLC Has $4.16 Million Holdings in IQVIA Holdings Inc. $IQV

Morningstar Investment Management LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 19.0% in the fourth quarter, Holdings Channel reports. The firm owned 18,444 shares of the medical research company’s stock after selling 4,339 shares during the quarter. Morningstar Investment Management LLC’s holdings in IQVIA were worth $4,158,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA during the fourth quarter worth $25,000. Physician Wealth Advisors Inc. grew its stake in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth $27,000. Westside Investment Management Inc. grew its stake in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the period. Finally, Measured Wealth Private Client Group LLC acquired a new position in IQVIA in the third quarter valued at about $30,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock opened at $168.28 on Monday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market cap of $28.09 billion, a price-to-earnings ratio of 20.85, a price-to-earnings-growth ratio of 1.61 and a beta of 1.18. The stock’s 50-day moving average is $169.72 and its 200-day moving average is $197.45. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has authorized a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. UBS Group decreased their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Royal Bank Of Canada assumed coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price for the company. Finally, Evercore reissued an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $225.69.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.